Email us for help
A new clinical trial is open combining low dose melphalan, a drug commonly used at high doses for stem cell transplant, and high dose intravenous Vitamin C. Learn more about how these two treatments work synergistically and why they have been combined in a clinical trial at the University of Iowa. The University of Iowa has unique experience with IV Vitamin C and Dr. Yogesh Jethava joins Myeloma Crowd Radio to share this fascinating open study now enrolling patients.
Dr. Yogesh Jethava is Associate Professor and Director of the Multiple Myeloma program as well as Associate Director of the Blood and Marrow Program at the University of Iowa. Prior to this appointment, he was director of the Bone Marrow and Stem Cell Transplant Services Division of Hematology Oncology at the Winthrop P. Rockefeller Cancer Institute at University of Arkansas for Medical Sciences or UAMS where he established the first fully functional allo transplant unit. There, he was Director and Attending Physician for the Leukemia and Lymphoma Subspecialty Clinic.
Dr. Jethava is an International Myeloma Working Group member and part of the EMBT malignancy working group and is a member of the Experimental Therapeutics groups and others. He reviews abstracts for publications like blood leukemia in the Blood Cancer Journal, and he is also working on studies that involves high dose vitamin C infusions for plasma cell disorders like myeloma.